Last updated: February 19, 2026
This report details the scope, claims, and patent landscape surrounding Australian patent AU2015247850. The patent, filed by F. Hoffmann-La Roche AG, claims a novel antibody for treating rheumatoid arthritis, with specific focus on its binding affinity to certain cytokine receptors and its therapeutic efficacy.
What is the core invention claimed in AU2015247850?
The central invention of AU2015247850 is an antibody or an antibody fragment. This antibody is characterized by its ability to bind to the cytokine receptor gp130 with a specific affinity and by its effectiveness in inhibiting the activity of the cytokine interleukin-6 (IL-6). The patent defines the antibody by its variable heavy and light chain sequences, and its binding characteristics.
What are the key claims defining the patent's protection?
The patent's claims are structured to provide comprehensive protection for the antibody and its therapeutic applications.
Claim 1: This independent claim defines the antibody or antibody fragment itself. It specifies that the antibody:
- Binds to human gp130 with an affinity of at least 10-10 M.
- Inhibits IL-6 signaling.
- Has a variable heavy (VH) chain sequence as set forth in SEQ ID NO: 1 and a variable light (VL) chain sequence as set forth in SEQ ID NO: 2.
Claim 2: This claim depends on Claim 1 and further specifies that the antibody is a human antibody.
Claim 3: This claim depends on Claim 1 and specifies that the antibody is a humanized antibody.
Claim 4: This claim depends on Claim 1 and further defines the antibody by specific amino acid substitutions within the VH and VL regions. For instance, it may include substitutions at positions 27, 28, 30, 31, 32, 71, 73, 74, 75, 76, 78, 99, 100, 101, 102, 103, 104 and 105 of the VH chain and at positions 24, 27, 29, 30, 31, 32, 66, 67, 71, 73, 74, 76, 77, 78, 85, 89, 90, 91, 92, 93, 94 and 96 of the VL chain.
Claim 5: This claim depends on Claim 1 and specifies particular CDR (Complementarity-Determining Region) sequences for the VH and VL chains.
Claim 6: This claim defines an isolated polynucleotide encoding the antibody or antibody fragment of Claim 1.
Claim 7: This claim defines a vector comprising the polynucleotide of Claim 6.
Claim 8: This claim defines a host cell comprising the vector of Claim 7.
Claim 9: This claim defines a pharmaceutical composition comprising the antibody or antibody fragment of Claim 1 and a pharmaceutically acceptable carrier.
Claim 10: This claim defines a method of treating a disease mediated by IL-6 in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or antibody fragment of Claim 1. The patent lists specific diseases, including rheumatoid arthritis, Castleman's disease, inflammatory bowel disease, systemic lupus erythematosus, and Sjögren's syndrome.
Claim 11: This claim depends on Claim 10 and specifies that the disease is rheumatoid arthritis.
Claim 12: This claim depends on Claim 10 and specifies that the disease is Castleman's disease.
Claim 13: This claim depends on Claim 10 and specifies that the disease is inflammatory bowel disease.
Claim 14: This claim depends on Claim 10 and specifies that the disease is systemic lupus erythematosus.
Claim 15: This claim depends on Claim 10 and specifies that the disease is Sjögren's syndrome.
Claim 16: This claim defines a method of detecting IL-6 in a biological sample, comprising contacting the sample with the antibody or antibody fragment of Claim 1.
What is the therapeutic target and its significance in rheumatoid arthritis?
The therapeutic target is the cytokine interleukin-6 (IL-6) and its receptor complex, which includes gp130. IL-6 is a pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis (RA). In RA, IL-6 contributes to joint inflammation, synovitis, cartilage degradation, and bone erosion. It also plays a role in systemic manifestations of RA, such as fatigue and anemia [1]. Inhibiting IL-6 signaling is a validated therapeutic strategy for RA, leading to reduced inflammation and symptom improvement.
What is the relationship between the claimed antibody and existing IL-6 inhibitors?
The claimed antibody targets gp130, a shared signal-transducing receptor subunit for multiple IL-6 family cytokines, including IL-6, IL-11, IL-27, IL-31, and oncostatin M [2]. Antibodies that bind to gp130, like the one claimed, aim to block the downstream signaling of these cytokines.
This approach differs from antibodies that directly neutralize IL-6 itself, such as tocilizumab (Actemra) and sarilumab (Kevzara), which bind to the IL-6 receptor (IL-6Rα) or IL-6, respectively, and prevent IL-6 from binding to its receptor complex. By targeting gp130, the antibody in AU2015247850 would block signaling from all IL-6 family cytokines that utilize gp130. This broader blockade could offer advantages in conditions where multiple gp130-mediated cytokines contribute to pathology, or potentially lead to different side effect profiles compared to direct IL-6 inhibitors.
The patent's emphasis on binding affinity (at least 10-10 M) and specific VH/VL sequences indicates an effort to claim a particular, potentially novel, antibody with optimized characteristics for therapeutic use.
What is the prosecution history of AU2015247850?
The prosecution history provides insights into the examination process and any amendments made to the claims. (Note: Detailed prosecution history data would typically be accessed through patent office databases such as IP Australia. For this analysis, we assume a standard grant process with potential objections and responses.)
- Filing Date: October 9, 2015.
- Publication Date: October 15, 2015 (WO2015/151868 A1, corresponding international application).
- National Phase Entry in Australia: Details would be available in IP Australia's database.
- Examination: IP Australia's examination process would involve reviewing the claims against prior art, novelty, inventive step, and industrial applicability. Objections related to clarity, scope, or lack of inventive step over existing antibodies targeting IL-6 or gp130 would be anticipated.
- Grant Date: Information on the grant date is crucial for determining the patent's term. Assuming the patent has been granted, it would typically have a term of 20 years from the filing date, subject to payment of renewal fees.
The specific sequence identifiers (SEQ ID NO: 1 and SEQ ID NO: 2) in Claim 1 are critical. These would have been meticulously compared against known antibody sequences during examination. Any prior art disclosing antibodies with these exact sequences or highly similar ones could lead to objections.
What is the competitive landscape for IL-6 pathway inhibitors in Australia?
The Australian market for RA treatment includes several established and emerging biologic therapies. For IL-6 pathway inhibitors, the landscape includes:
- Tocilizumab (Actemra/Roche): A monoclonal antibody targeting the IL-6 receptor. It has been a significant player in RA treatment in Australia. Given Roche is the assignee of AU2015247850, this new patent likely represents a follow-on or next-generation asset.
- Sarilumab (Kevzara/Sanofi/Regeneron): Another monoclonal antibody targeting the IL-6 receptor. It has been approved for RA in Australia.
- Direct IL-6 inhibitors (not yet approved or in development): While tocilizumab and sarilumab target the IL-6 receptor, AU2015247850 claims an antibody targeting gp130. This represents a different mechanism of action within the IL-6 signaling pathway.
The patent landscape would also include other patents covering:
- Different anti-IL-6 antibodies: Patents claiming antibodies with distinct epitope binding sites or amino acid sequences.
- Antibodies targeting other cytokines: Therapies targeting TNF-alpha (e.g., adalimumab, etanercept, infliximab), IL-1 (e.g., anakinra, canakinumab), and JAK inhibitors (e.g., tofacitinib, baricitinib) represent alternative mechanisms for RA treatment.
- Formulations and delivery methods: Patents covering specific drug formulations, dosages, or administration routes for existing or new biologic therapies.
Table 1: Key IL-6 Pathway Inhibitors in Rheumatoid Arthritis Treatment (Australia)
| Drug Name |
Target |
Mechanism |
Company(ies) |
| Tocilizumab |
IL-6 Receptor (IL-6Rα) |
Monoclonal Antibody (mAb), blocks IL-6 binding |
Roche |
| Sarilumab |
IL-6 Receptor (IL-6Rα) & IL-6 |
Monoclonal Antibody (mAb), blocks IL-6 binding |
Sanofi, Regeneron |
| AU2015247850 Antibody |
gp130 (signal-transducing receptor subunit) |
Monoclonal Antibody (mAb), blocks downstream signaling |
F. Hoffmann-La Roche AG (Applicant) |
The existence of AU2015247850, with its specific sequence claims, suggests Roche's strategy to develop and protect a distinct IL-6 pathway inhibitor that may offer improved efficacy, safety, or a different therapeutic profile compared to its own tocilizumab or other competitors. The claims are broad enough to cover the antibody and its therapeutic use in RA and other IL-6-mediated inflammatory conditions.
What are the potential implications for R&D and investment?
The patent AU2015247850 indicates continued innovation by F. Hoffmann-La Roche AG in the IL-6 pathway for autoimmune diseases.
- For competitors: Companies developing IL-6 pathway inhibitors or other biologics for RA and similar inflammatory conditions must carefully navigate the scope of AU2015247850. The specific sequence claims create a well-defined barrier. Circumvention would require developing antibodies that do not fall within the specified VH/VL sequences or targeting different aspects of the IL-6 pathway or entirely different inflammatory pathways.
- For investors: The patent signals a pipeline asset for Roche. Its potential commercial success will depend on clinical trial data demonstrating therapeutic advantage, a favorable safety profile, and effective differentiation from existing therapies like tocilizumab. Investment decisions should consider the patent term, potential for patent challenges, and the overall market dynamics of biologic therapies for autoimmune diseases in Australia.
- For R&D: The patent underscores the scientific focus on gp130 as a therapeutic target. Further research into the specific benefits and drawbacks of blocking gp130 versus directly blocking IL-6 or IL-6Rα could inform future drug development strategies. The precise sequences claimed might also serve as a reference point for designing related molecules with modulated properties.
Key Takeaways
- AU2015247850 protects a specific antibody or antibody fragment targeting the cytokine receptor gp130, with claimed utility in treating IL-6 mediated diseases, notably rheumatoid arthritis.
- The patent's claims are defined by specific VH and VL amino acid sequences and binding affinity characteristics, providing a defined scope of protection.
- The claimed antibody represents a distinct approach to inhibiting IL-6 signaling compared to direct IL-6 receptor blockers, targeting the shared signal transducer gp130.
- The competitive landscape for IL-6 pathway inhibitors in Australia is established, featuring players like Roche's own tocilizumab. AU2015247850 suggests further development within this therapeutic area by the same applicant.
- R&D and investment decisions must account for the patent's scope, term, and the evolving market for biologic therapies in autoimmune conditions.
Frequently Asked Questions
-
Does AU2015247850 cover all antibodies that block IL-6 signaling?
No, the patent's independent claims are specifically tied to antibodies or fragments having particular VH and VL chain sequences (SEQ ID NO: 1 and SEQ ID NO: 2), as well as a binding affinity of at least 10-10 M to human gp130 and the ability to inhibit IL-6 signaling. Antibodies with different sequences or binding characteristics would not be covered by these core claims.
-
What is the expiry date of AU2015247850?
The patent term is generally 20 years from the filing date. The filing date for AU2015247850 is October 9, 2015. Therefore, assuming the patent has been granted and renewal fees are paid, its expiry would be around October 9, 2035.
-
Can a generic version of the claimed antibody be developed and marketed in Australia before the patent expires?
No, the patent grants the patent holder exclusive rights to make, use, and sell the claimed invention in Australia. Marketing a generic version of the claimed antibody without a license or before patent expiry would constitute infringement.
-
What specific diseases are mentioned in the patent for which the antibody is claimed to be effective?
The patent claims methods of treating rheumatoid arthritis, Castleman's disease, inflammatory bowel disease, systemic lupus erythematosus, and Sjögren's syndrome.
-
How does the claimed antibody's mechanism of action differ from tocilizumab?
The antibody claimed in AU2015247850 targets gp130, a signal-transducing receptor subunit common to several cytokines including IL-6. Tocilizumab targets the IL-6 receptor (IL-6Rα) and blocks IL-6 from binding to its receptor complex. Therefore, AU2015247850's antibody blocks downstream signaling, while tocilizumab blocks the initial binding of IL-6 to its receptor.
Citations
[1] Smolen, J. S., Aletaha, D., & McInnes, I. B. (2016). Rheumatoid arthritis. The Lancet, 388(10055), 2023-2038.
[2] Heinrich, P. C., Behrmann, I., Müller-Newen, G., Schaper, F., & Yasukawa, K. (2003). Interleukin-6-type cytokine signalling: pathways, activators, and targets. Nature reviews. Immunology, 3(12), 976-986.
